DHS 157.65(5)(a)(a) For each patient or human research subject receiving brachytherapy who may not be released under s. DHS 157.62 (8), a licensee shall do both the following: DHS 157.65(5)(a)1.1. Not quarter the patient or the human research subject in the same room as a person who is not receiving brachytherapy. DHS 157.65(5)(a)2.2. Visibly post a “Radioactive Materials” sign on the door of the patient’s or human research subject’s room and note on the door or in the patient’s or human research subject’s chart where and how long visitors may stay in the patient’s or human research subject’s room. DHS 157.65(5)(b)(b) A licensee shall have available, near each treatment room, emergency response equipment to respond to a source that is any of the following: DHS 157.65(5)(b)2.2. Inadvertently lodged within the patient following removal of the source applicators. DHS 157.65(5)(c)(c) A licensee shall notify the radiation safety officer or his or her designee and an authorized user as soon as possible if the patient or human research subject has a medical emergency, and immediately if the patient dies. DHS 157.65(6)(6) Calibration measurements of brachytherapy sources. DHS 157.65(6)(a)(a) Prior to the first medical use of brachytherapy sources, a licensee shall either comply with par. (b) or do all of the following: DHS 157.65(6)(a)3.3. Use published protocols accepted by nationally recognized bodies to meet the requirements of subds. 1. and 2. DHS 157.65(6)(b)(b) Instead of a licensee making its own measurements as required in par. (a), the licensee may use measurements provided by the source manufacturer or by a calibration laboratory accredited by the American Association of Physicists in Medicine that are made in accordance with par. (a). DHS 157.65(6)(c)(c) A licensee shall mathematically correct the outputs or activities determined in par. (a) for physical decay at intervals consistent with one percent physical decay. DHS 157.65(6m)(a)(a) Licensees who use strontium-90 for ophthalmic treatments must ensure that certain activities as specified in par. (b) of this section are performed by either of the following: DHS 157.65(6m)(a)2.a.a. Is identified as an ophthalmic physicist on a specific medical use license issued by the department, the NRC or an agreement state, or permit issued by the NRC or an agreement state broad scope medical use licensee, medical use permit issued by an NRC master material licensee, or permit issued by an NRC master material licensee broad scope medical use permittee. DHS 157.65(6m)(a)2.b.b. Holds a master’s or doctor’s degree in physics, medical physics, other physical sciences, engineering, or applied mathematics from an accredited college or university. DHS 157.65(6m)(a)2.c.c. Has successfully completed one year of full-time training in medical physics and an additional year of full-time work experience under the supervision of a medical physicist. DHS 157.65(6m)(a)2.d.d. Has documented training in the creation, modification, and completion of written directives. DHS 157.65(6m)(a)2.e.e. Has documented training in procedures for administrations requiring a written directive. DHS 157.65(6m)(a)2.f.f. Has documented training in performing the calibration measurements of brachytherapy sources as detailed in sub. (6). DHS 157.65(6m)(b)1.1. Calculate the activity of each strontium-90 source that is used to determine the treatment times for ophthalmic treatments. The decay must be based on the activity determined under sub. (6). DHS 157.65(6m)(b)2.2. Assist the licensee in developing, implementing, and maintaining written procedures to provide high confidence that the administration is in accordance with the written directive. These procedures shall include the frequencies that the individual meeting the requirements in par. (a) will observe treatments, review the treatment methodology, calculate treatment time for the prescribed dose, and review records to verify that the administrations were in accordance with the written directives.